Conference Dates
June 12 – 17, 2022
Abstract
Oncolytic viruses (OVs), as a therapeutic vaccine, offer an elegant approach to cancer therapy. On the one side they have the ability to cause direct tumor cell lysis, on the other side they can stimulate immune responses directed against the tumor. By expressing endogenous or heterologous fusion glycoproteins, an enhanced intratumoral spread via syncytia formation can be achieved. Rapid and efficient fusion of infected cells may result in large multinucleated syncytia, in which cells quickly die before high titers are reached [1]. Prospective treatment with OVs will require manufacturing processes that enable the production of a very high number of doses with high titers. As a first step towards this goal, suspension cell substrates were identified to develop a highly efficient and scalable production process of a novel hyper-fusogenic hybrid of vesicular stomatitis virus and Newcastle disease virus (rVSV-NDV).
Please click Download on the upper right corner to see the full abstract.
Recommended Citation
Sven Göbel, Marie Dorn, Karim Jaén Chavez, Ingo Jordan, Volker Sandig, Jennifer Altomente, Yvonne Genzel, and Udo Reichl, "Production of a fusogenic oncolytic rVSV-NDV virus in perfusion processes" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/60